## Supplementary digital content

Supplementary Table 1. Overview of short-term studies

|  |  |  |
| --- | --- | --- |
| **Vector** **Study 331-10-231****(NCT01396421)** | **Beacon** **Study 331-10-230****(NCT01393613)** | **Lighthouse** **Study 14644A****(NCT01810380)** |
| **636 patients treated** | **674 patients treated**  | **464 patients treated** |
| Fixed dosing | Fixed dosing | Flexible dosing |
| Brexpiprazole 0.25 mg/day (N=90)Brexpiprazole 2 mg/day (N=182)Brexpiprazole 4 mg/day (N=180)Placebo (N=184) | Brexpiprazole 1 mg/day (N=120)Brexpiprazole 2 mg/day (N=186)Brexpiprazole 4 mg/day (N=184)Placebo (N=184) | Brexpiprazole 2–4 mg/day (N=150)Placebo (N=161)Quetiapine XR 400–800 mg/day (N=153) |

Supplementary Table 2. Overview of long-term studies

|  |  |
| --- | --- |
| **Zenith****Study 331-10-237****(NCT01397786)** | **Lighthouse extension****Study 14644B****(NCT01810783)** |
| **1031 patients treated**De novo (N=224)Beacon prior brexpiprazole (N=219)Beacon prior placebo (N=67)Vector prior brexpiprazole (N=217)Vector prior placebo (N=61)Equator prior brexpiprazole (N=169)Equator prior placebo (N=74) | **209 patients treated**Prior brexpiprazole (N=66)Prior placebo (N=64)Prior quetiapine (N=79) |
| Flexible dosing | Flexible dosing |
| Brexpiprazole 1–4 mg/day | Brexpiprazole 1–4 mg/day |

|  |  |  |
| --- | --- | --- |
| **Sex** | **Females** | **Males** |
| **Baseline status** | **Normal** | **>1x ULN** | **Normal** | **>1x ULN** |
| **Treatment** | **Placebo** | **Brexpiprazole 2 mg** | **Brexpiprazole 4 mg** | **Placebo** | **Brexpiprazole 2 mg** | **Brexpiprazole 4 mg** | **Placebo** | **Brexpiprazole 2 mg** | **Brexpiprazole 4 mg** | **Placebo** | **Brexpiprazole 2 mg** | **Brexpiprazole 4 mg** |
| **Baseline; mean (median) [n]** | 10.60 (9.87) [104] | 9.66 (8.62) [114] | 11.33 (9.44) [111] | 68.47 (48.38) [35] | 79.42 (52.85) [21] | 60.43 (50.42) [29] | 6.68 (6.47) [170] | 6.12 (5.39) [171] | 6.83 (6.21) [164] | 25.04 (21.11) [59] | 27.51 (20.13) [61] | 24.30 (20.65) [60] |
| **Change Week 6; mean (median) [n]** | -0.43 (-0.91) [56] | 5.93 (4.46) [79] | 6.74 (5.65) [75] | -41.48 (-34.25) [21] | -48.13 (-28.67) [16] | -28.69 (-26.13) [23] | 0.44 (-0.17) [112] | 2.47 (1.84) [115] | 2.85 (1.68) [108] | -10.25(-11.84) [37] | -14.38 (-11.21) [41] | -10.38 (-8.07) [43] |
| ULN: upper limit of normal |

Supplementary Table 3: Fixed-dose, short-term studies – mean changes from baseline by dose, sex and baseline prolactin status